Niraparib as maintenance for platinum-sensitive ovarian cancer - results from ENGOT-OV16/NOVA trial

Dr. Mirza on Efficacy of Niraparib/Bevacizumab Combo in Recurrent Ovarian CancerПодробнее

Niraparib Maintenance Therapy in Ovarian CancerПодробнее

Results of Niraparib/Bevacizumab Combo in Platinum-Sensitive Recurrent Ovarian CancerПодробнее

Niraparib Maintenance for Recurrent Ovarian CancerПодробнее

Dr. Matulonis on the NOVA Trial of Niraparib Maintenance Therapy in Ovarian CancerПодробнее

NOVA Phase III trial of niraparib in platinum-sensitive ovarian cancer patientsПодробнее

Next steps for niraparib for ovarian cancer following on from the ENGOT-OV16/NOVA trialПодробнее

Comparison of trials of niraparib, olaparib and rucaparib in ovarian cancerПодробнее

Results of ENGOT-OV16/NOVA Phase III trial of niraparib in platinum-sensitive ovarian cancerПодробнее

Overview of ENGOT-OV16/NOVA of niraparib in ovarian cancer and why the results were not surprisingПодробнее

Mansoor Raza Mirza:Подробнее

Trial design of ENGOT-OV16/NOVA Phase III trial of niraparib in platinum-sensitive ovarian cancerПодробнее

Results from the ENGOT-OV16/NOVA trial: efficacy and safety of niraparib in ovarian cancerПодробнее